← 產業報告目錄

Peptide Cancer Vaccine Market, By Pipeline Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, and Phase III), By Application (Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Gastric Cancer, Prostate Cancer, and Breast Cancer), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版商 Coherent Market Insights出版日期 2026-07-24頁數 259報告編號 CMR-b54784dce6

授權報價

Single User Price$4,500 USD
Site License Price$7,000 USD
Enterprisewide Price (Global Site License)$10,000 USD
洽詢購買 申請 Sample

報告摘要

The Peptide Cancer Vaccine Market is estimated to be valued at USD 1.8 Bn in 2026 and is expected to reach USD 8.2 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 24.3% from 2026 to 2033. The market is undergoing a major transformation mainly driven by rising adoption of personalized cancer immunotherapies, increasing demand for targeted treatment options, and growing emphasis on antitumor immune response solutions. Peptide cancer vaccines, including personalized, shared-antigen, and multipeptide formulations, enable immunity to recognize tumor antigens efficiently while addressing tumor heterogeneity, immune escape, and safety standards. The market includes a wide array of product applications like melanoma, lung cancer, breast cancer, prostate cancer, gastrointestinal cancers, hematological malignancies, and solid tumor treatment. Patients and healthcare providers are focusing on precise immune activation and therapeutic approaches to enhance treatment outcomes, ensure tumor control, and maintain quality of life. The advancements in neoantigen identification, peptide synthesis, and adjuvant delivery tools are improving vaccine performance, especially in patients with treatment-resistant or recurrent cancers. In addition, the growing use of genomic sequencing and combination immunotherapy regimens helps optimize patient selection and immune response, thereby improving clinical outcomes and reducing burden of cancer treatment. Market Dynamics The market is witnessing major momentum owing to increasing prevalence of cancer, rising investment in tumor-specific immunotherapy, and the growing need for treatments capable of generating durable immune responses. The market’s growth is largely driven by biotechnology companies and research institutions seeking precise, adaptable, and safe therapeutic vaccine platforms, especially for melanoma, glioblastoma, prostate cancer, ovarian cancer, pancreatic cancer, and other malignancies requiring targeted immune intervention. Tumor-associated antigens, synthetic peptides, immune adjuvants, and antigen-presenting cell technologies play a central role in vaccine development, thereby helping activate cytotoxic T cells, improve tumor recognition, and limit disease progression. The rising focus on individualized treatment, recurrence prevention, and immune-based oncology is strengthening the demand for peptide cancer vaccines. The expansion of neoantigen discovery programs is fueling market growth. This is mainly driven by increasing adoption of genomic profiling, availability of advanced peptide synthesis platforms, and biomarker-guided vaccines designed according to tumor mutations. Combination approaches involving checkpoint inhibitors, chemotherapy, and immune-stimulating agents help improve response rates and overcome tumor-induced immune suppression. The rising demand for less toxic cancer therapies is also propelling the market. Oncologists, immunologists, clinical researchers, pharmaceutical developers, diagnostic laboratories, and specialized cancer centers play a crucial role in evaluating and advancing peptide vaccine candidates. As understanding of tumor immunology grows, the market is expected to benefit from clinical development, improved patient selection, and the introduction of more personalized, effective, and scalable cancer vaccination solutions. Key Features of the Study • This report provides in-depth analysis of the Peptide Cancer Vaccine Market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the Peptide Cancer Vaccine Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Marker Therapeutics, Inc., Agenus, Merck, BrightPath Biotherapeutics, Boston Biomedical, VAXON Biotech, Nouscom, Lytix Biopharma, ISA Pharmaceuticals, Generex Biotechnology, OncoTherapy Science, Enzo Life Science, Immatics Biotechnologies, SELLAS Life Sciences Group, Ultimovacs, Celldex therapeutics, Immunomic Therapeutics, Inc. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The Peptide Cancer Vaccine Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Peptide Cancer Vaccine Market Market Segmentation • By Pipeline Phase (Revenue, USD Bn, 2021-2033) o Research o Preclinical o Phase-I o Phase-I/II o Phase-II o Phase-III • By Application (Revenue, USD Bn, 2021-2033) o Colorectal Cancer o Lung Cancer o Pancreatic Cancer o Gastric Cancer o Prostate Cancer o Breast Cancer • By Region (Revenue, USD Bn, 2021-2033) o North America  U.S.  Canada o Latin America  Brazil  Mexico  Argentina  Rest of Latin America o Europe  Germany  U.K.  France  Italy  Spain  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC  Israel  Rest of Middle East o Africa  South Africa  Central Africa  North Africa • Key Players Insights o Marker Therapeutics, Inc. o Agenus o Merck o BrightPath Biotherapeutics o Boston Biomedical o VAXON Biotech o Nouscom o Lytix Biopharma o ISA Pharmaceuticals o Generex Biotechnology o OncoTherapy Science o Enzo Life Science o Immatics Biotechnologies o SELLAS Life Sciences Group o Ultimovacs o Celldex therapeutics o Immunomic Therapeutics, Inc.
目錄 Table of Contents
Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Overview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Pipeline Phase  Market Snapshot, By Application  Market Snapshot, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Market Trends o Key Developments o Disease Type Approval o Collaboration/Merge/Acquisition o Regulatory Landscape o PEST Analysis o Porter’s Five Forces Analysis o Epidemiology o Robust Pipeline Analysis 4. Global Peptide Cancer Vaccine Market, By Pipeline Phase, 2021 – 2033, (USD Billion) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022– 2033  Segment Trends o Research  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Preclinical  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Phase-I  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Phase-I/II  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Phase-II  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Phase-III  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) 5. Global Peptide Cancer Vaccine Market, By Application, 2021 – 2033, (USD Billion) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022– 2033  Segment Trends o Colorectal Cancer  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Lung Cancer  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Pancreatic Cancer  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Gastric Cancer  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Prostate Cancer  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) o Breast Cancer  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion) 6. Global Peptide Cancer Vaccine Market, By Region, 2021 – 2033, (USD Billion) o Introduction  Market Share Analysis, By Region, 2026 and 2033 (%)  Y-o-Y Growth Analysis, For Regions, 2022–2033  Regional Trends o North America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion) o Brazil o Mexico o Argentina o Rest of Latin America o Europe  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion) o U.K. o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion) o GCC o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Pipeline Phase, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)  Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Billion) o North Africa o Central Africa o South Africa 7. Competitive Landscape o Heat Map Analysis o Market Share Analysis o Company Profile  Marker Therapeutics, Inc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Agenus o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Merck o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  BrightPath Biotherapeutics o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Boston Biomedical o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  VAXON Biotech o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Nouscom o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Lytix Biopharma o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  ISA Pharmaceuticals o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Generex Biotechnology o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  OncoTherapy Science o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Enzo Life Science o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Immatics Biotechnologies o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  SELLAS Life Sciences Group o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Ultimovacs o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Celldex therapeutics o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Immunomic Therapeutics, Inc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies o Analyst Views 8. Section o References o Research Methodology o About Us
圖表清單 List of Tables & Figures
NA NA

提及公司

o Marker TherapeuticsInc.o Agenuso Mercko BrightPath Biotherapeuticso Boston Biomedicalo VAXON Biotecho Nouscomo Lytix Biopharmao ISA Pharmaceuticalso Generex Biotechnologyo OncoTherapy Scienceo Enzo Life Scienceo Immatics Biotechnologieso SELLAS Life Sciences Groupo Ultimovacso Celldex therapeuticso Immunomic TherapeuticsInc.

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們